Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted Therapies

Read full text Summarise with VIRAT
Authors: Filippo Spriano, Alberto J. Arribas, F. Zhang, Elisa Civanelli, Maria Luisa Mangoni, Francesco Buonocore, Francesco Bertoni
Cited by: 0
References: 14

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ABSTRACT Introduction Marginal zone lymphoma (MZL) is an indolent yet incurable B‐cell malignancy in which targeted agents such as BTK and PI3K inhibitors frequently fail due to resistance or toxicity. Antimicrobial peptides (AMPs), evolutionarily conserved effectors of innate immunity, possess selective cytotoxicity against malignant cells by exploiting tumor‐specific membrane alterations. Methods Peptides were synthesized and tested for their anti‐proliferative activity in MZL cell lines. Results We evaluated the antitumor activity of seven natural AMPs, including Antarctic fish–derived trematocines and chionodracine variants, and amphibian temporins, against MZL cell lines (VL51, Karpas1718) and derivatives resistant to BTK, PI3Kδ, or PI3Kα/δ inhibitors. Among them, W‐trematocine and temporin L demonstrated potent dose‐dependent cytotoxicity with IC 50 values of 5.7–10 µM, maintaining full activity in all resistant models. Other peptides showed moderate activity, while chionodracine‐1 was inactive. Notably, W‐trematocine displayed minimal toxicity toward nonmalignant cells in prior studies, underscoring its selectivity. AMP‐mediated killing, driven by membrane disruption and non‐apoptotic death pathways, bypassed conventional resistance mechanisms, suggesting therapeutic potential in relapsed/refractory disease. Conclusion Our findings highlight natural AMPs as promising candidates for development in drug‐resistant MZL, warranting further optimization and preclinical validation.

Fields of Study & Subjects

Antimicrobial Peptides and Activities Lymphoma Diagnosis and Treatment Chemical Synthesis and Analysis

Publication details

Journal / source
eJHaem
Volume
7
Issue
2
Pages
e70267–e70267
Publication date
30 March 2026
Language
EN